Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad
German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.
You may also be interested in...
The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.
Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.
The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.